396 related articles for article (PubMed ID: 19995325)
1. Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin.
Signorovitch JE; Sheng Duh M; Sengupta A; Gu A; Grant R; Raut M; Mody SH; Schein J; Fisher AC; Ng D
Curr Med Res Opin; 2010 Feb; 26(2):355-63. PubMed ID: 19995325
[TBL] [Abstract][Full Text] [Related]
2. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
[TBL] [Abstract][Full Text] [Related]
3. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of length of stay, total costs, and treatment success between intravenous moxifloxacin 400 mg and levofloxacin 750 mg among hospitalized patients with community-acquired pneumonia.
Friedman H; Song X; Crespi S; Navaratnam P
Value Health; 2009; 12(8):1135-43. PubMed ID: 19695010
[TBL] [Abstract][Full Text] [Related]
5. Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US.
Raut M; Schein J; Mody S; Grant R; Benson C; Olson W
Curr Med Res Opin; 2009 Sep; 25(9):2151-7. PubMed ID: 19601711
[TBL] [Abstract][Full Text] [Related]
6. Moxifloxacin versus levofloxacin for treatment of acute rhinosinusitis: a retrospective database analysis of treatment duration, outcomes, and charges.
Keating KN; Friedman HS; Perfetto EM
Curr Med Res Opin; 2006 Feb; 22(2):327-33. PubMed ID: 16466604
[TBL] [Abstract][Full Text] [Related]
7. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
Anzueto A; Niederman MS; Pearle J; Restrepo MI; Heyder A; Choudhri SH;
Clin Infect Dis; 2006 Jan; 42(1):73-81. PubMed ID: 16323095
[TBL] [Abstract][Full Text] [Related]
8. An economic evaluation of levofloxacin versus cefuroxime axetil in the outpatient treatment of adults with community-acquired pneumonia.
Rittenhouse BE; Stinnett AA; Dulisse B; Henke CJ; Potter L; Parasuraman B; Martens LL; Williams RR; Kojak C
Am J Manag Care; 2000 Mar; 6(3):381-9. PubMed ID: 10977438
[TBL] [Abstract][Full Text] [Related]
9. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
[TBL] [Abstract][Full Text] [Related]
10. Pharmacoeconomic considerations associated with the use of intravenous-to-oral moxifloxacin for community-acquired pneumonia.
Davis SL; Delgado G; McKinnon PS
Clin Infect Dis; 2005 Jul; 41 Suppl 2():S136-43. PubMed ID: 15942880
[TBL] [Abstract][Full Text] [Related]
11. A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium.
Martin M; Moore L; Quilici S; Decramer M; Simoens S
Curr Med Res Opin; 2008 Mar; 24(3):737-51. PubMed ID: 18230196
[TBL] [Abstract][Full Text] [Related]
12. Moxifloxacin versus standard therapy in patients with pneumonia hospitalized after failure of preclinical anti-infective treatment.
Wenisch C; Krause R; Széll M; Laferl H
Infection; 2006 Aug; 34(4):190-5. PubMed ID: 16896576
[TBL] [Abstract][Full Text] [Related]
13. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
[TBL] [Abstract][Full Text] [Related]
14. Evidence for moxifloxacin in community-acquired pneumonia: the impact of pharmaco-economic considerations on guidelines.
Simoens S
Curr Med Res Opin; 2009 Oct; 25(10):2447-57. PubMed ID: 19678752
[TBL] [Abstract][Full Text] [Related]
15. A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: results from the MOTIV trial.
Lloyd A; Holman A; Evers T
Curr Med Res Opin; 2008 May; 24(5):1279-84. PubMed ID: 18358083
[TBL] [Abstract][Full Text] [Related]
16. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center.
Warren DK; Shukla SJ; Olsen MA; Kollef MH; Hollenbeak CS; Cox MJ; Cohen MM; Fraser VJ
Crit Care Med; 2003 May; 31(5):1312-7. PubMed ID: 12771596
[TBL] [Abstract][Full Text] [Related]
17. [Factors effecting the duration of hospitalization and mortality in patients with community-acquired pneumonia].
Pişkin N; Aydemir H; Oztoprak N; Akduman D; Celebi G; Seremet Keskin A
Mikrobiyol Bul; 2009 Oct; 43(4):597-606. PubMed ID: 20084912
[TBL] [Abstract][Full Text] [Related]
18. The hospital admission decision for patients with community-acquired pneumonia. Results from the pneumonia Patient Outcomes Research Team cohort study.
Fine MJ; Hough LJ; Medsger AR; Li YH; Ricci EM; Singer DE; Marrie TJ; Coley CM; Walsh MB; Karpf M; Lahive KC; Kapoor WN
Arch Intern Med; 1997 Jan; 157(1):36-44. PubMed ID: 8996039
[TBL] [Abstract][Full Text] [Related]
19. Preferences for home vs hospital care among low-risk patients with community-acquired pneumonia.
Coley CM; Li YH; Medsger AR; Marrie TJ; Fine MJ; Kapoor WN; Lave JR; Detsky AS; Weinstein MC; Singer DE
Arch Intern Med; 1996 Jul; 156(14):1565-71. PubMed ID: 8687265
[TBL] [Abstract][Full Text] [Related]
20. The economic effect of oral linezolid versus intravenous vancomycin in the outpatient setting: the payer perspective.
McKinnon PS; Carter CT; Girase PG; Liu LZ; Carmeli Y
Manag Care Interface; 2007 Jan; 20(1):23-34. PubMed ID: 17310650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
